No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

CoolSculpting Elite: Next-Generation Fat Reduction System Launches

Editor: What To Know

  • CoolSculpting Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.
  • The innovative new C-shaped applicators are designed to complement the body’s natural curves for improved fit and comfort during initial tissue draw and features up to an 18% larger cooling area as compared to the previous generation CoolSculpting applicators.
  • “The dual applicators allow us to treat two areas at the same time, safely freezing twice the fat compared to using a single CoolSculpting applicator, which helps us save on time.

January 26, 2021

CoolSculpting Elite, its next-generation fat reduction system with applicators designed to complement the body’s natural curves. Allergan Aesthetics, an AbbVie company announced the news today.

CoolSculpting Elite harnesses proven CoolSculpting® technology to target, freeze, and eliminate treated fat cells. CoolSculpting Elite is FDA cleared to treat visible fat bulges in nine areas of the body including the thigh, abdomen, and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), upper arm, and the submental and submandibular areas.

“The number one aesthetic concern for consumers is excess body fat1. CoolSculpting® has been an industry-leader, creating the market for non-invasive fat reduction over 10 years ago. Now CoolSculpting® Elite builds on that heritage with a completely re-invented next-generation technology that delivers results,” says Carrie Strom, Senior Vice President, AbbVie, and President, Global Allergan Aesthetics. “We understand the challenges of today’s world and as people prepare to go from being online to spending more time in person, CoolSculpting® Elite can help them address their bothersome fat.”

CoolSculpting Elite will launch with a new applicator collection, which includes seven different shapes and sizes. The innovative new C-shaped applicators are designed to complement the body’s natural curves for improved fit and comfort during initial tissue draw and features up to an 18% larger cooling area as compared to the previous generation CoolSculpting applicators. The clinical significance of these data has not been established.

“CoolSculpting® is a critical part of my business and a device I’ve relied on to help my patients achieve their desired outcome of reducing stubborn fat.” said Dr. Sabrina Fabi, Board Certified Dermatologist and Associate Research Director at Cosmetic Laser Surgery in San Diego. “The dual applicators allow us to treat two areas at the same time, safely freezing twice the fat compared to using a single CoolSculpting applicator, which helps us save on time. With the Elite applicator collection we are able to treat a wide range of body areas and personalize each patient’s treatment plan.”

Allergan Aesthetics™ is now taking orders for the CoolSculpting® Elite device, and the first units will ship in Q1 2021.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy